Dr. George Tidmarsh, the Food and Drug Administration’s top drug regulator, was placed on administrative leave and is considering resigning, citing a “toxic” environment at the FDA.
Tidmarsh, who leads the FDA’s Center for Drug Evaluation and Research, was placed on leave Friday “after the Office of the General Counsel and the Office of the Inspector General were notified of serious concerns about his personal conduct,” Emily Hilliard, an HHS spokeswoman, told ABC News in a statement.
STAT News, a health, science and medicine-oriented publication, reported Sunday that Tidmarsh was accused of using his regulatory authority to financially harm a former business associate.
FDA Awards First-Ever National Priority Vouchers to Nine Sponsors
For Immediate Release:
October 16, 2025
The U.S. Food and Drug Administration today announced nine voucher recipients under the new Commissioner’s National Priority Voucher (CNPV) pilot program. Each recipient has a product with significant potential to address a major national priority, such as meeting a large unmet medical need, reducing downstream health care utilization, addressing a public health crisis, boosting domestic manufacturing, or increasing medication affordability with Most Favored Nation pricing.
Under Trump, FDA Seeks To Abandon Expert Reviews of New Drugs
September 16, 2025 EDT
FDA leaders under President Donald Trump are moving to abandon a decades-old policy of asking outside experts to review drug applications, a move critics say would shield the agency’s decisions from public scrutiny.
The agency “would like to get away” from assembling panels of experts to examine and vote on individual drugs, because “I don’t think they’re needed,” said George Tidmarsh, head of the FDA’s Center for Drug Evaluation and Research. He relayed the message Tuesday at a meeting of health care product makers and Wednesday to an FDA advocacy group.
https://jheor.org/post/3439-under-trump-fda-seeks-to-abandon-expert-reviews-of-new-drugs
